Presented at ESMO: the HARMONi-6 study on a bispecific antibody therapy for squamous NSCLC
About this episode
Shun Lu discusses the phase 3 HARMONi-6 trial of ivonescimab plus chemotherapy for advanced squamous non-small-cell lung cancer.
Shun Lu joins Ben Abbott of The Lancet to discuss the phase 3 HARMONi-6 trial of ivonescimab plus chemotherapy as first-line treatment in advanced squamous non-small-cell lung cancer, which is being presented at ESMO 2025. Click here to read the full article Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thela...
People in this episode
Host: Ben Abbott
Guest: Shun Lu
Topics covered
- cancer treatment
- clinical trials
- bispecific antibodies
- lung cancer
- medical research
Keywords
- HARMONi-6
- ivonescimab
- squamous NSCLC
- ESMO 2025
- clinical trial
Mentioned in this episode
Organizations: The Lancet, ESMO
Products: ivonescimab
Places: advanced squamous non-small-cell lung cancer
More episodes of The Lancet in conversation with
- Louise Chappell and Na’ama Carlin on Personal Cancer Stories
- Susannah Stanway on the London Global Cancer Week
- Carlos Monteiro, Camila Corvalán, and Phil Baker on Ultra-Processed Foods and Human Health
- Presented at ASH: the EPCORE FL-1 study on epcoritamab in follicular lymphoma
- Presented at ESMO: the POTOMAC study on immunotherapy in non-muscle-invasive bladder cancer
- Stephen Chan on the Lancet Commission on addressing the global hepatocellular carcinoma burden
Explore listener stats, chart rankings, contacts and more on the The Lancet in conversation with podcast page.